Ipodate sodium

Ipodate sodium
Clinical data
Trade names	Oragrafin
Routes of; administration	oral, Intravenous
ATC code	V08AC08 (WHO) ;
Identifiers
	IUPAC name sodium 3-(3-{[(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoate;
CAS Number	5587-89-3;
PubChem CID	14651;
ChemSpider	13984;
UNII	F604ZKI910;
ChEMBL	ChEMBL1201033;
CompTox Dashboard (EPA)	DTXSID9048271 ;
ECHA InfoCard	100.013.587
Chemical and physical data
Formula	C12H12I3N2NaO2
Molar mass	619.943 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	168–169 °C (334–336 °F)
	SMILES CN(C)/C=N/c1c(cc(c(c1I)CCC(=O)[O-])I)I.[Na+];
	InChI InChI=1S/C12H13I3N2O2.Na/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19;/h5-6H,3-4H2,1-2H3,(H,18,19);/q;+1/p-1/b16-6+;; Key:ZFHZUGUCWJVEQC-FPUQOWELSA-M;

Ipodate sodium (sodium iopodate) is an iodine-containing radiopaque contrast media used for X-rays. The drug is given orally and the resulting contrast allows for easy resolution of the bile duct and gall bladder.